Evidence map›Paper›PMID 39371366›Full record

ArticleOpen forum infectious diseases2024

Highly Heterogeneous Kaposi Sarcoma-Associated Herpesvirus Oral Shedding Kinetics Among People With and Without Kaposi Sarcoma and Human Immunodeficiency Virus Coinfection.

Elizabeth M Krantz, Innocent Mutyaba, Janet Nankoma, Fred Okuku, Corey Casper, Jackson Orem, David A Swan, Warren Phipps, Joshua T Schiffer

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Elizabeth M KrantzVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID https://orcid.org/0009-0000-0029-8511
Innocent MutyabaUganda Cancer Institute, Kampala, Uganda.
Janet NankomaUganda Cancer Institute, Kampala, Uganda.
Fred OkukuUganda Cancer Institute, Kampala, Uganda.
Corey CasperVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Jackson OremUganda Cancer Institute, Kampala, Uganda.
David A SwanVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Warren PhippsVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID https://orcid.org/0000-0003-3564-8571
Joshua T SchifferVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI CONNIE L CELUM · 1988 to 2026
$104.9M
Project 3U54CA190146 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI CASPER, COREY · 2014 to 2019
$4.1M
Expanding independent research capacity in HIV-associated malignancies in UgandaD43TW009759 · FIC · FRED HUTCHINSON CANCER RESEARCH CENTER · PI OREM, JACKSON, PHIPPS, WARREN · 2014 to 2023
$3.0M
Characterizing determinants of primary KSHV infection among children and adolescents in UgandaR01CA239593 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI OREM, JACKSON, PHIPPS, WARREN · 2019 to 2023
$2.9M
Human Herpesvirus-8 Replication and Kaposi Sarcoma Response to TreatmentK23CA150931 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PHIPPS, WARREN · 2011 to 2015
$714k
FIC NIH HHS D43 TW009759NCI NIH HHS K23 CA150931NCI NIH HHS P30 CA015704NCI NIH HHS R01 CA239593NCI NIH HHS U54 CA190146NIAID NIH HHS P30 AI027757
6 · The paper itself

Abstract

Background: An improved understanding of oral Kaposi sarcoma-associated herpesvirus (KSHV) viral dynamics could provide insights into transmission risk and guide vaccine development. Methods: We evaluated KSHV oral shedding dynamics in Ugandan adults stratified by Kaposi sarcoma (KS) and human immunodeficiency virus (HIV) status. Participants were followed for ≥4 weeks, with daily home oral swab collection to quantify KSHV using polymerase chain reaction. Shedding rates were defined by number of days with KSHV DNA detected divided by total days with swabs and compared by group using hurdle models. Results: Two hundred ninety-five participants were enrolled; median age was 35 years (range, 18-71 years), and 134 (45%) were male. KSHV was detected more frequently among participants with KS (HIV positive [HIV Conclusions: Oral KSHV shedding is highly heterogeneous across Ugandan adults with and without KS and HIV. Persistent shedding is associated with higher median viral loads regardless of HIV and KS status.

Indexed as

HHV-8HIVKaposi sarcomaKSHVviral shedding dynamics

Identifiers

PMID39371366
PMCPMC11450676

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.